サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：mRNAワクチンの世界市場：2023-2033年
市場調査レポート
商品コード
1379266

mRNAワクチンの世界市場：2023-2033年

mRNA Vaccines Market Report 2023-2033
出版日: | 発行: Visiongain Reports Ltd. | ページ情報: 英文 215 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=198.76円

ご注意:
Single UserとTeamライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

mRNAワクチンの世界市場：2023-2033年
出版日: 2023年11月08日
発行: Visiongain Reports Ltd.
ページ情報: 英文 215 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のmRNAワクチンの市場規模は、2033年にかけてCAGR 10.5%で成長すると予測されています。

潜在的な癌治療薬としてのmRNAワクチンについては、20年以上にわたって広範な研究が行われてきましたが、これまでその成果は限定的でした。しかし最近になって、癌ワクチンに対する研究の注目度が急上昇しています。この急増は、免疫チェックポイント阻害剤の使用によって特定の悪性腫瘍に顕著かつ永続的な反応が見られたことと、技術の進歩に促されています。ペムブロリズマブ (通称キイトルーダ) と併用する個別化ワクチンmRNA-4157 (V940) の第3相臨床試験の開始は、2023年7月26日にModernaとMerckによって発表されました。本試験の主要評価項目は、これらの患者の術後無再発生存率を評価することであり、2029年までに最終結果が得られると予想されています。

当レポートでは、世界のmRNAワクチンの市場を調査し、市場概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 レポートの概要

第2章 エグゼクティブサマリー

第3章 市場概要

  • 主な調査結果
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 市場機会
  • COVID-19の影響分析
  • ポーター分析
  • PEST分析

第4章 mRNAワクチン市場の分析：タイプ別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 自己増幅型mRNAベースワクチン
  • 従来の非増幅mRNAベースワクチン

第5章 mRNAワクチン市場の分析：用途別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 癌
  • 感染症
  • 自己免疫疾患
  • その他

第6章 mRNAワクチン市場の分析：エンドユーザー別

  • 主要調査結果
  • 市場魅力度指数
  • 市場規模の推移・予測
  • 病院・診療所
  • 研究機関
  • その他

第7章 mRNAワクチン市場の分析：地域別

  • 主要調査結果
  • 市場規模の推移・予測

第8章 北米のmRNAワクチン市場の分析

第9章 欧州のmRNAワクチン市場の分析

第10章 アジア太平洋のmRNAワクチン市場の分析

第11章 ラテンアメリカのmRNAワクチン市場の分析

第12章 中東・アフリカのmRNAワクチン市場の分析

第13章 企業プロファイル

  • 競合情勢
  • 戦略的展望
  • BioNTech SE
  • GSK plc
  • Daiichi Sankyo
  • Ethris GmbH
  • AIM Vaccine
  • Arcturus Therapeutics Inc.
  • CureVac
  • AstraZeneca
  • Sanofi
  • Sino Biopharmaceutical Co., Ltd.

第14章 総論・提言

  • Visiongainからの総論
  • 市場参入企業への提言
図表

List of Tables

  • Table 1 mRNA Vaccines Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
  • Table 2 mRNA Vaccines & Therapeutics: Companies & Delivery Platforms
  • Table 3 mRNA Vaccines in Clinical Trials: June 2023
  • Table 4 mRNA Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 5 mRNA Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 6 mRNA Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 7 mRNA Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 8 mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 Infectious Disease Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 Autoimmune Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 Hospitals and Clinics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 Research Organisations Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 mRNA Vaccines Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 North America mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 North America mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 North America mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 North America mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 U.S. mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 Canada mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 Europe mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 Europe mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Europe mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Europe mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 31 Germany mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 UK mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 33 France mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 Italy mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 Spain mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 Russia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 Rest of Europe mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 Asia Pacific mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Asia Pacific mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Asia Pacific mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Japan mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 China mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 India mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 Australia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 South Korea mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 South-East Asia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 Latin America mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Latin America mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 Latin America mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 52 Brazil mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 53 Mexico mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 54 Rest of Latin America mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 55 MEA mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 56 MEA mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 57 MEA mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 58 MEA mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 59 GCC mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 60 South Africa mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 61 Rest of MEA mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 62 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 63 Pfizer Inc.: Product/Pipeline Benchmarking
  • Table 64 Pfizer Inc.: Strategic Outlook
  • Table 65 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 66 Moderna, Inc.: Product/Pipeline Benchmarking
  • Table 67 Moderna, Inc.: Strategic Outlook
  • Table 68 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 69 BioNTech SE: Product/Pipeline Benchmarking
  • Table 70 BioNTech SE: Strategic Outlook
  • Table 71 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 72 GSK plc: Product/Pipeline Benchmarking
  • Table 73 Daiichi Sankyo: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 74 Daiichi Sankyo: Product/Pipeline Benchmarking
  • Table 75 Daiichi Sankyo: Strategic Outlook
  • Table 76 Ethris GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 77 Ethris GmbH: Product/Pipeline Benchmarking
  • Table 78 Ethris GmbH: Strategic Outlook
  • Table 79 AIM Vaccine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 80 AIM Vaccine: Product/Pipeline Benchmarking
  • Table 81 AIM Vaccine: Strategic Outlook
  • Table 82 Arcturus Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 83 Arcturus Therapeutics Inc.: Product/Pipeline Benchmarking
  • Table 84 CureVac: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 CureVac: Product/Pipeline Benchmarking
  • Table 86 CureVac: Strategic Outlook
  • Table 87 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 88 AstraZeneca: Product/Pipeline Benchmarking
  • Table 89 AstraZeneca: Strategic Outlook
  • Table 90 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 91 Sanofi: Product/Pipeline Benchmarking
  • Table 92 Sino Biopharmaceutical Co., Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 Sino Biopharmaceutical Co., Ltd.: Product/Pipeline Benchmarking
  •  

List of Figures

  • Figure 1 mRNA Vaccines Market Segmentation
  • Figure 2 mRNA Vaccines Market by Vaccine Type: Market Attractiveness Index
  • Figure 3 mRNA Vaccines Market by Application: Market Attractiveness Index
  • Figure 4 mRNA Vaccines Market by End-users: Market Attractiveness Index
  • Figure 5 mRNA Vaccines Market Attractiveness Index by Region
  • Figure 6 mRNA Vaccines Market: Market Dynamics
  • Figure 7 mRNA Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 8 mRNA Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 9 mRNA Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 10 mRNA Vaccines Market by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 11 mRNA Vaccines Market: Porter's Five Forces Analysis
  • Figure 12 mRNA Vaccines Market: PEST Analysis
  • Figure 13 mRNA Vaccines Market Attractiveness Index by Vaccine Type
  • Figure 14 mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 15 mRNA Vaccines Market Share Forecast by Vaccine Type, 2023, 2028, 2033 (%)
  • Figure 16 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 17 Self-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 18 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 19 Conventional Non-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 20 mRNA Vaccines Market Attractiveness Index by Vaccine Type
  • Figure 21 mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 22 mRNA Vaccines Market Share Forecast by Application, 2023, 2028, 2033 (%)
  • Figure 23 Cancer Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 24 Cancer Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 25 Infectious Disease Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 26 Infectious Disease Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 27 Autoimmune Diseases Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 28 Autoimmune Diseases Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 29 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 30 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 31 mRNA Vaccines Market Attractiveness Index by End-users
  • Figure 32 mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 33 mRNA Vaccines Market Share Forecast by End-users, 2023, 2028, 2033 (%)
  • Figure 34 Hospitals and Clinics Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 35 Hospitals and Clinics Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 36 Research Organisations Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 37 Research Organisations Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 38 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 39 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 40 mRNA Vaccines Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
  • Figure 41 mRNA Vaccines Market Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 42 mRNA Vaccines Market by Region, 2023-2033 (US$ Mn)
  • Figure 43 North America mRNA Vaccines Market Attractiveness Index
  • Figure 44 North America mRNA Vaccines Market by Region, 2023, 2028 & 2033 (US$ million)
  • Figure 45 North America mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ million)
  • Figure 46 North America mRNA Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 47 North America mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 48 North America mRNA Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 49 North America mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 50 North America mRNA Vaccines Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 51 North America mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 52 North America mRNA Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 53 U.S. mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 54 Canada mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 55 Europe mRNA Vaccines Market Attractiveness Index
  • Figure 56 Europe mRNA Vaccines Market by Region, 2023, 2028 & 2033 (US$ million)
  • Figure 57 Europe mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ million, AGR %)
  • Figure 58 Europe mRNA Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 59 Europe mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 60 Europe mRNA Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 61 Europe mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 62 Europe mRNA Vaccines Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 63 Europe mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 64 Europe mRNA Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 65 Germany mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 66 UK mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 67 France mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 68 Italy mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 69 Spain mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 70 Russia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 71 Rest of Europe mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 72 Asia Pacific mRNA Vaccines Market Attractiveness Index
  • Figure 73 Asia Pacific mRNA Vaccines Market by Region, 2023, 2028 & 2033 (US$ million)
  • Figure 74 Asia Pacific mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ million, AGR %)
  • Figure 75 Asia Pacific mRNA Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 76 Asia Pacific mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 77 Asia Pacific mRNA Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 78 Asia Pacific mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 79 Asia Pacific mRNA Vaccines Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 80 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Asia Pacific mRNA Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 82 Japan mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 83 China mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 84 India mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 85 Australia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 86 South Korea mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 87 South-East Asia mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 88 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 89 Latin America mRNA Vaccines Market Attractiveness Index
  • Figure 90 Latin America mRNA Vaccines Market by Region, 2023, 2028 & 2033 (US$ million)
  • Figure 91 Latin America mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ million)
  • Figure 92 Latin America mRNA Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 93 Latin America mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 94 Latin America mRNA Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 95 Latin America mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 96 Latin America mRNA Vaccines Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 97 Latin America mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 98 Latin America mRNA Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 99 Brazil mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 100 Mexico mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 101 Rest of Latin America mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 102 MEA mRNA Vaccines Market Attractiveness Index
  • Figure 103 MEA mRNA Vaccines Market by Region, 2023, 2028 & 2033 (US$ million)
  • Figure 104 MEA mRNA Vaccines Market Forecast by Country, 2023-2033 (US$ million)
  • Figure 105 MEA mRNA Vaccines Market Share Forecast by Country, 2023 & 2033 (%)
  • Figure 106 MEA mRNA Vaccines Market Forecast by Vaccine Type, 2023-2033 (US$ Million, AGR %)
  • Figure 107 MEA mRNA Vaccines Market Share Forecast by Vaccine Type, 2023 & 2033 (%)
  • Figure 108 MEA mRNA Vaccines Market Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 109 MEA mRNA Vaccines Market Share Forecast by Application, 2023 & 2033 (%)
  • Figure 110 MEA mRNA Vaccines Market Forecast by End-users, 2023-2033 (US$ Million, AGR %)
  • Figure 111 MEA mRNA Vaccines Market Share Forecast by End-users, 2023 & 2033 (%)
  • Figure 112 GCC mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 113 South Africa mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 114 Rest of MEA mRNA Vaccines Market Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 115 Pfizer Inc.: Net Revenue, 2015-2022 (US$ million, AGR%)
  • Figure 116 Pfizer Inc.: Regional Market Shares (%), 2022
  • Figure 117 Pfizer Inc.: R&D, 2015-2022 (US$ million, AGR%)
  • Figure 118 Moderna, Inc.: Net Revenue, 2016-2022 (US$ million, AGR%)
  • Figure 119 Moderna, Inc.: R&D, 2016-2022 (US$ million, AGR%)
  • Figure 120 BioNTech SE: Net Revenue, 2018-2022 (US$ million, AGR%)
  • Figure 121 BioNTech SE: R&D, 2018-2022 (US$ million, AGR%)
  • Figure 122 GSK plc: Net Revenue, 2015-2022 (US$ million, AGR%)
  • Figure 123 GSK plc: Regional Market Shares (%), 2022
  • Figure 124 GSK plc: R&D, 2015-2022 (US$ million, AGR%)
  • Figure 125 AstraZeneca: Net Revenue, 2015-2022 (US$ million, AGR%)
  • Figure 126 AstraZeneca: Regional Market Shares (%), 2022
  • Figure 127 AstraZeneca: R&D, 2015-2022 (US$ million, AGR%)
  • Figure 128 Sanofi: Net Revenue, 2018-2022 (US$ million, AGR%)
  • Figure 129 Sanofi: Regional Market Shares (%), 2022
  • Figure 130 Sanofi: R&D, 2018-2022 (US$ million, AGR%)
目次
Product Code: PHA1289

The global mRNA Vaccines market is projected to grow at a CAGR of 10.5% by 2033.

“The mRNA Vaccines Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Extensive research has been conducted on mRNA vaccines as potential cancer therapeutics for a period exceeding two decades, yielding limited success. In recent times, there has been a notable surge in research attention towards cancer vaccines. This surge has been prompted by the remarkable and enduring responses witnessed in certain malignancies through the use of immune checkpoint inhibitors, as well as advancements in technology. The initiation of a phase 3 clinical trial for the personalised vaccine mRNA-4157 (also referred to as V940) in conjunction with pembrolizumab (commonly known as Keytruda) was announced by Moderna and Merck on 26 July 2023. This trial aims to evaluate the efficacy of the combination therapy in high-risk patients who have previously undergone surgical intervention for melanoma. The objective of the trial is to recruit a total of 1,089 patients who are at stages IIb to IV. The primary endpoint of the trial is to assess the post-surgical recurrence-free survival of these patients. The conclusive outcomes are anticipated to be available by the year 2029.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the mRNA vaccines market evolving?
  • What is driving and restraining the mRNA vaccines market?
  • How will each mRNA vaccines submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each mRNA vaccines submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading mRNA vaccines markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the mRNA vaccines projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of

mRNA vaccines projects taking place now and over the next 10 years?

  • Is there a greater need for product commercialisation to further scale the mRNA vaccines market?
  • Where is the mRNA vaccines market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the mRNA vaccines market today, and over the next 10 years:

  • Our 215-page report provides 93 tables and 130 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the mRNA vaccines market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Vaccine Type

  • Self-amplifying mRNA-based Vaccines
  • Conventional Non-amplifying mRNA-based Vaccines

Application

  • Cancer
  • Infectious Disease
  • Autoimmune Diseases
  • Others

End-users

  • Hospitals and Clinics
  • Research Organisations
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South-East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the mRNA Vaccines Market, 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Pfizer Inc
  • Moderna, Inc
  • BioNTech SE
  • AstraZeneca
  • Sanofi
  • GSK plc
  • Daiichi Sankyo
  • Ethris GmbH
  • AIM Vaccine
  • Arcturus Therapeutics Inc
  • CureVac
  • Sino Biopharmaceutical Co., Ltd.

Overall world revenue for mRNA Vaccines Market, 2023 to 2033 in terms of value the market will surpass US$11,700.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the “mRNA Vaccines Market, 2023 to 2033” report help you?

In summary, our 210+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for mRNA Vaccines Market 2023 to 2033, with forecasts for Vaccine type, application, and end-users, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 22 key national markets - See forecasts for the mRNA Vaccines Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 12 of the major companies involved in the mRNA Vaccines Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the mRNA Vaccines Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to mRNA Vaccines Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Growing Diverse Applications of mRNA Post COVID-19 Vaccine Success
      • 3.2.1.2 Significant Research Funding to Boost Market Growth
      • 3.2.1.3 Technological Advances Driving the Market Growth
      • 3.2.1.4 Rising mRNA Vaccine-based Clinical Trials
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Scalability and Cost-Effectiveness is Still a Major Bottleneck
      • 3.2.2.2 Significant Storage Challenges in Low-income Countries Likely to Challenge Industry Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 mRNA Cancer Vaccines
      • 3.2.3.2 Analytics, Machine Learning and Cloud Data Warehousing
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Supplier Power
    • 3.4.2 Buyer Power
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
    • 3.5.1 Political Factors
    • 3.5.2 Economic Factors
    • 3.5.3 Social Factors
    • 3.5.4 Technological Factors

4 mRNA Vaccines Market Analysis by Vaccine Type

  • 4.1 Key Findings
  • 4.2 Vaccine Type Segment: Market Attractiveness Index
  • 4.3 mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 4.4 Self-amplifying mRNA-based Vaccines
    • 4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2023 & 2033 (%)
  • 4.5 Conventional Non-amplifying mRNA-based Vaccines
    • 4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2023 & 2033 (%)

5 mRNA Vaccines Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 mRNA Vaccines Market Size Estimation and Forecast by Application
  • 5.4 Cancer
    • 5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Infectious Disease
    • 5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)
  • 5.6 Autoimmune Diseases
    • 5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.6.2 Market Share by Region, 2023 & 2033 (%)
  • 5.7 Others
    • 5.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 5.7.2 Market Share by Region, 2023 & 2033 (%)

6 mRNA Vaccines Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 6.4 Hospitals and Clinics
    • 6.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Research Organisations
    • 6.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Others
    • 6.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)

7 mRNA Vaccines Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America mRNA Vaccines Market Analysis

  • 8.1 Key Findings
  • 8.2 North America mRNA Vaccines Market Attractiveness Index
  • 8.3 North America mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 8.4 North America mRNA Vaccines Market Size Estimation and Forecast by Country
  • 8.5 North America mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 8.6 North America mRNA Vaccines Market Size Estimation and Forecast by Application
  • 8.7 North America mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 8.8 U.S. mRNA Vaccines Market Analysis
  • 8.9 Canada mRNA Vaccines Market Analysis

9 Europe mRNA Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe mRNA Vaccines Market Attractiveness Index
  • 9.3 Europe mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 Europe mRNA Vaccines Market Size Estimation and Forecast by Country
  • 9.5 Europe mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 9.6 Europe mRNA Vaccines Market Size Estimation and Forecast by Application
  • 9.7 Europe mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 9.8 Germany mRNA Vaccines Market Analysis
  • 9.9 UK mRNA Vaccines Market Analysis
  • 9.10 France mRNA Vaccines Market Analysis
  • 9.11 Italy mRNA Vaccines Market Analysis
  • 9.12 Spain mRNA Vaccines Market Analysis
  • 9.13 Russia mRNA Vaccines Market Analysis
  • 9.14 Rest of Europe mRNA Vaccines Market Analysis

10 Asia Pacific mRNA Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific mRNA Vaccines Market Attractiveness Index
  • 10.3 Asia Pacific mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 10.6 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Application
  • 10.7 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 10.8 Japan mRNA Vaccines Market Analysis
  • 10.9 China mRNA Vaccines Market Analysis
  • 10.10 India mRNA Vaccines Market Analysis
  • 10.11 Australia mRNA Vaccines Market Analysis
  • 10.12 South Korea mRNA Vaccines Market Analysis
  • 10.13 South-East Asia mRNA Vaccines Market Analysis
  • 10.14 Rest of Asia Pacific mRNA Vaccines Market Analysis

11 Latin America mRNA Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America mRNA Vaccines Market Attractiveness Index
  • 11.3 Latin America mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Latin America mRNA Vaccines Market Size Estimation and Forecast by Country
  • 11.5 Latin America mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 11.6 Latin America mRNA Vaccines Market Size Estimation and Forecast by Application
  • 11.7 Latin America mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 11.8 Brazil mRNA Vaccines Market Analysis
  • 11.9 Mexico mRNA Vaccines Market Analysis
  • 11.10 Rest of Latin America mRNA Vaccines Market Analysis

12 MEA mRNA Vaccines Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA mRNA Vaccines Market Attractiveness Index
  • 12.3 MEA mRNA Vaccines Market by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 MEA mRNA Vaccines Market Size Estimation and Forecast by Country
  • 12.5 MEA mRNA Vaccines Market Size Estimation and Forecast by Vaccine Type
  • 12.6 MEA mRNA Vaccines Market Size Estimation and Forecast by Application
  • 12.7 MEA mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 12.8 GCC mRNA Vaccines Market Analysis
  • 12.9 South Africa mRNA Vaccines Market Analysis
  • 12.10 Rest of MEA mRNA Vaccines Market Analysis

13 Company Profiles

  • 13.1 Pfizer Inc.
    • 13.1.1 Company Snapshot
    • 13.1.2 Company Overview
    • 13.1.3 Financial Analysis
      • 13.1.3.1 Net Revenue, 2015-2022
      • 13.1.3.2 Regional Market Shares, 2022
      • 13.1.3.3 R&D, 2015-2022
    • 13.1.4 Product/Pipeline Benchmarking
    • 13.1.5 Strategic Outlook
  • 13.2 Moderna, Inc.
    • 13.2.1 Company Snapshot
    • 13.2.2 Company Overview
    • 13.2.3 Financial Analysis
      • 13.2.3.1 Net Revenue, 2016-2022
      • 13.2.3.2 R&D, 2016-2022
    • 13.2.4 Product/Pipeline Benchmarking
    • 13.2.5 Strategic Outlook
  • 13.3 BioNTech SE
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2018-2022
      • 13.3.3.2 R&D, 2018-2022
    • 13.3.4 Product/Pipeline Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 GSK plc
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2015-2022
      • 13.4.3.2 Regional Market Shares, 2022
      • 13.4.3.3 R&D, 2015-2022
    • 13.4.4 Product/Pipeline Benchmarking
  • 13.5 Daiichi Sankyo
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Product/Pipeline Benchmarking
    • 13.5.4 Strategic Outlook
  • 13.6 Ethris GmbH
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Product/Pipeline Benchmarking
    • 13.6.4 Strategic Outlook
  • 13.7 AIM Vaccine
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Product/Pipeline Benchmarking
    • 13.7.4 Strategic Outlook
  • 13.8 Arcturus Therapeutics Inc.
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Product/Pipeline Benchmarking
  • 13.9 CureVac
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Product/Pipeline Benchmarking
    • 13.9.4 Strategic Outlook
  • 13.10 AstraZeneca
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2015-2022
      • 13.10.3.2 Regional Market Shares, 2022
      • 13.10.3.3 R&D, 2015-2022
    • 13.10.4 Product/Pipeline Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Sanofi
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2018-2022
      • 13.11.3.2 Regional Market Shares, 2022
      • 13.11.3.3 R&D, 2018-2022
    • 13.11.4 Product/Pipeline Benchmarking
  • 13.12 Sino Biopharmaceutical Co., Ltd.
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Product/Pipeline Benchmarking

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players